Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
about
Pharmaceutical policies: effects of financial incentives for prescribersThe effect of financial incentives on the quality of health care provided by primary care physiciansPharmaceutical policies: effects of restrictions on reimbursementImpact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trialsBehaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic reviewSwitching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.Prescribing efficiency of proton pump inhibitors in China: influence and future directionsThe impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis.Policies to enhance prescribing efficiency in europe: findings and future implications.The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimentaDo newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in FinlandSimulation of the AUC changes after generic substitution in patients.Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future.Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians.Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications.Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.Statin medication in patients treated with antiepileptic drugs in Norway.Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies.The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.Drug expenditure of high-cost patients and their characteristics in Finland.Probable warfarin-simvastatin interaction.Ageing, physical activity and mortality--a 42-year follow-up study.Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications.Evaluation of statin utilization in the Republic of Macedonia during 2013-2016.Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi
P2860
Q24188018-B87BA9C3-0BE5-49E9-A624-BBBA6A86135DQ24234504-0A96708A-1B61-47F9-8D4F-9AC512498FC3Q24236533-0EFA0442-3460-4ACA-A2AE-5D09D0D8EC78Q26776293-1912DC53-C96B-46A6-916E-4E659FDEF832Q26866161-583954D4-6145-463E-8F82-E18EF5A876B4Q30978981-F7A32F5A-6E95-4E16-B447-864A2DC4D9F5Q33816182-B6F3A147-951B-4543-B1BF-66B155E1CD62Q34693650-152EC3E3-C4EE-4277-AFFD-3EB1F42715FCQ35021173-E10B28C3-357F-4298-897A-8A9A8E819CBEQ35083824-A0D21024-D925-4770-9238-AECA5378BBE1Q35155250-11C88168-1723-4ED2-A2E8-656912F2934BQ35770269-7D3B9BF0-E018-4B8C-A324-BC3CC9B9EB20Q35990559-0A0132DB-5B50-4DC9-9B40-919163D6A1B2Q36853539-CC1AC7C2-1818-4E92-B94F-B0439F7DD75EQ37116797-78444455-15AF-475C-B579-C63B907D5378Q37161532-B7044733-40E2-4A3E-80DE-8973FA2D6516Q37574860-52B2A2D4-412A-49EB-8D2E-10EEA2CDB1ADQ37639328-002219F2-A84C-4421-AD7D-ED671548D72AQ37847158-776F7659-F64C-4EDD-AF3D-37FB25994868Q38263092-863DAEB6-E047-49FB-9A8A-BD8A3A7B84A5Q38878608-EAF65D1C-E287-43F3-B08A-EDA2AC5AF055Q39109315-74097AB5-286D-4E6B-A5BE-F59622B4BDD8Q39513393-3ABA5320-71D7-4691-8FFA-B794EE781E20Q39940166-6F40E77F-7B71-4E43-8A76-29F917531EC1Q40322708-CE5856A7-6530-44E8-8CF4-9B9F1FA90663Q41136557-471C078A-D691-40CE-B3AC-8BD5A1323BEBQ41654265-EED8E038-DA22-411A-9C51-24A24724F2CDQ43102979-6A56F2C4-5AB6-4228-866F-3B7503E3C4B6Q43918109-2BCD0732-875B-4D1B-8B54-4C79690C9C4DQ43948677-4EAA2912-59C7-4E22-95E4-8E19AFF93CC2Q45877071-F10ED60C-5D5F-485A-93D8-A9183C20A7F0Q47285139-F94B1ABE-1D14-4B39-876B-18713CAAD49BQ48200779-E75887C5-E625-42B5-BD84-950A702F186DQ48302949-C59971FF-1987-427B-A874-FF7EC09C7384Q51184451-21AAAD25-137F-4533-9B22-BE4EFF59B6D9Q51750408-5AC28914-95F4-4055-AA0C-C024A95BE8DEQ53094333-73700AE6-000F-4347-87AE-C6156143A9EDQ55078654-F0C4D908-B1BD-44F3-BC9C-D242E90CEBB2Q55474688-647E0B3C-EA45-463E-A364-75A9FFA2E72DQ56828549-C6751BA8-27E7-42C6-8A45-F80AE302DAC4
P2860
Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Switching statins in Norway af ...... nationwide prescription study.
@ast
Switching statins in Norway af ...... nationwide prescription study.
@en
type
label
Switching statins in Norway af ...... nationwide prescription study.
@ast
Switching statins in Norway af ...... nationwide prescription study.
@en
prefLabel
Switching statins in Norway af ...... nationwide prescription study.
@ast
Switching statins in Norway af ...... nationwide prescription study.
@en
P2093
P2860
P1476
Switching statins in Norway af ...... nationwide prescription study.
@en
P2093
Marit Rønning
Solveig Sakshaug
Svetlana Skurtveit
P2860
P304
P356
10.1111/J.1365-2125.2007.02907.X
P407
P577
2007-04-18T00:00:00Z